On November 13, 2017, Bill Gates, founder of Microsoft, announced that he planned to invest $100 million in research ventures seeking a cure for Alzheimer’s disease and dementia. He invested $50 million in the Dementia Discovery Fund (DDF), and another $50 million will go to start-up ventures. The DDF, managed by SV Health, is a venture fund focused entirely on discovering and developing novel therapies for dementia. It was formed through the collaboration of leading pharmaceutical companies, the United Kingdom (UK) Department of Health and the charity Alzheimer’s Research UK. Seven leading pharmaceutical companies: Biogen, Eli Lilly . . .